World Health Organization Generic Protocol to Assess Drug-Resistant HIV among Children <18 Months of Age and Newly Diagnosed with HIV in Resource-Limited Countries

Silvia Bertagnolio, Martina Penazzato, Michael R. Jordan, Deborah Persaud, Lynne M. Mofenson, Diane E. Bennett

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Increased use of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in pregnant and breastfeeding women will result in fewer children infected with human immunodeficiency virus (HIV). However, among children infected despite prevention of mother-to-child transmission (PMTCT), a substantial proportion will acquire NNRTI-resistant HIV, potentially compromising response to NNRTI-based antiretroviral therapy (ART). In countries scaling up PMTCT and pediatric ART programs, it is crucial to assess the proportion of young children with drug-resistant HIV to improve health outcomes and support national and global decision making on optimal selection of pediatric first-line ART. This article summarizes a new World Health Organization surveillance protocol to assess resistance using remnant dried blood spot specimens from a representative sample of children aged <18 months being tested for early infant diagnosis.

Original languageEnglish (US)
Pages (from-to)S254-S260
JournalClinical Infectious Diseases
Volume54
Issue numberSUPPL. 4
DOIs
StatePublished - May 15 2012

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'World Health Organization Generic Protocol to Assess Drug-Resistant HIV among Children <18 Months of Age and Newly Diagnosed with HIV in Resource-Limited Countries'. Together they form a unique fingerprint.

Cite this